Verifying…
Home / Drug A–Z / Acetazolamide 250 Tablets_

Acetazolamide 250 Tablets_

NAFDAC Reg. No. A11-100010 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
Acetazolamide 250 Tablets_
NAFDAC number
A11-100010
Active ingredient
Acetazolamide
Strength
250 mg
Form
Tablet
Manufacturer
Not listed
Applicant (holder)
Fidson Healthcare PLC
Approved
1 Mar 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
28 Feb 2026
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Acetazolamide 250 Tablets_ is on the NAFDAC register with an active registration (A11-100010). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Acetazolamide 250 Tablets_ is used for

From the official U.S. FDA label for acetazolamide, the active ingredient registered with NAFDAC.

What it is used for

For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent.

Possible side effects

Body as a whole: Headache, malaise, fatigue, fever, flushing, growth retardation in children, flaccid paralysis, anaphylaxis Digestive: Gastrointestinal disturbances such as nausea, vomiting, diarrhea Hematological/Lymphatic: Blood dyscrasias such as aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia, thrombocytopenic purpura, melena Hepato-biliary disorders: Abnormal liver function, cholestatic jaundice, hepatic insufficiency, fulminant hepatic necrosis Metabolic/Nutritional: Metabolic acidosis, electrolyte imbalance, including hypokalemia, hyponatremia, osteomalacia with long-term phenytoin therapy, loss of appetite, taste alteration, hyper/hypoglycemia Nervous: Drowsiness, par …

Do not use if

Hypersensitivity to acetazolamide or any excipients in the formulation. Since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible. Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. …

Warnings

Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias, and anaphylaxis. Sensitizations may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of hypersensitivity or other serious reactions occur, discontinue use of this drug. Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported.

Pregnancy & breastfeeding

Pregnancy: Teratogenic effects Acetazolamide, administered orally or parenterally, has been shown to be teratogenic (defects of the limbs) in mice, rats, hamsters, and rabbits. There are no adequate and well-controlled studies in pregnant women. Acetazolamide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Acetazolamide 250 Tablets_

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Acetazolamide 250 Tablets_

What is in Acetazolamide 250 Tablets_?

Acetazolamide 250 Tablets_ contains Acetazolamide (250 mg), as tablet, according to its NAFDAC registration record.

Is Acetazolamide 250 Tablets_ registered with NAFDAC?

Yes. Acetazolamide 250 Tablets_ is listed on the NAFDAC register under registration number A11-100010, and its registration is active as of 28 October 2026.

Has Acetazolamide 250 Tablets_ been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Acetazolamide 250 Tablets_ in our automatically synced alert list.

How can I check that my pack of Acetazolamide 250 Tablets_ is genuine?

Run a free authenticity scan with the NAFDAC number A11-100010, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Acetazolamide 250 Tablets_ used for?

For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amel (Summarised from the official U.S. FDA label for acetazolamide. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Acetazolamide 250 Tablets_? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.